317 related articles for article (PubMed ID: 8499631)
1. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII.
Pittman DD; Alderman EM; Tomkinson KN; Wang JH; Giles AR; Kaufman RJ
Blood; 1993 Jun; 81(11):2925-35. PubMed ID: 8499631
[TBL] [Abstract][Full Text] [Related]
2. Development and characterization of recombinant ovine coagulation factor VIII.
Zakas PM; Gangadharan B; Almeida-Porada G; Porada CD; Spencer HT; Doering CB
PLoS One; 2012; 7(11):e49481. PubMed ID: 23152911
[TBL] [Abstract][Full Text] [Related]
3. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.
Jacquemin M; Lavend'homme R; Benhida A; Vanzieleghem B; d'Oiron R; Lavergne JM; Brackmann HH; Schwaab R; VandenDriessche T; Chuah MK; Hoylaerts M; Gilles JG; Peerlinck K; Vermylen J; Saint-Remy JM
Blood; 2000 Aug; 96(3):958-65. PubMed ID: 10910910
[TBL] [Abstract][Full Text] [Related]
4. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
5. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
[TBL] [Abstract][Full Text] [Related]
6. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
Saenko EL; Shima M; Gilbert GE; Scandella D
J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
[TBL] [Abstract][Full Text] [Related]
7. Amino acid residues 721-729 are required for full factor VIII activity.
Kjalke M; Heding A; Talbo G; Persson E; Thomsen J; Ezban M
Eur J Biochem; 1995 Dec; 234(3):773-9. PubMed ID: 8575434
[TBL] [Abstract][Full Text] [Related]
8. Light chain of factor VIII is sufficient for accelerating cleavage of von Willebrand factor by ADAMTS13 metalloprotease.
Cao W; Sabatino DE; Altynova E; Lange AM; Casina VC; Camire RM; Zheng XL
J Biol Chem; 2012 Sep; 287(39):32459-66. PubMed ID: 22854959
[TBL] [Abstract][Full Text] [Related]
9. Expression and characterization of a codon-optimized blood coagulation factor VIII.
Shestopal SA; Hao JJ; Karnaukhova E; Liang Y; Ovanesov MV; Lin M; Kurasawa JH; Lee TK; Mcvey JH; Sarafanov AG
J Thromb Haemost; 2017 Apr; 15(4):709-720. PubMed ID: 28109042
[TBL] [Abstract][Full Text] [Related]
10. Structure and function of the factor VIII gene and protein.
Thompson AR
Semin Thromb Hemost; 2003 Feb; 29(1):11-22. PubMed ID: 12640560
[TBL] [Abstract][Full Text] [Related]
11. Coagulation factor VIII regulates von Willebrand factor homeostasis invivo.
Cao W; Trask AR; Bignotti AI; George LA; Doshi BS; Sabatino DE; Yada N; Zheng L; Camire RM; Zheng XL
J Thromb Haemost; 2023 Dec; 21(12):3477-3489. PubMed ID: 37726033
[TBL] [Abstract][Full Text] [Related]
12. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
Siner JI; Iacobelli NP; Sabatino DE; Ivanciu L; Zhou S; Poncz M; Camire RM; Arruda VR
Blood; 2013 May; 121(21):4396-403. PubMed ID: 23372167
[TBL] [Abstract][Full Text] [Related]
13. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules.
Barrow RT; Healey JF; Gailani D; Scandella D; Lollar P
Blood; 2000 Jan; 95(2):564-8. PubMed ID: 10627463
[TBL] [Abstract][Full Text] [Related]
14. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
Yada K; Nogami K; Takeyama M; Ogiwara K; Wakabayashi H; Shima M
J Thromb Haemost; 2015 Oct; 13(10):1843-53. PubMed ID: 26278069
[TBL] [Abstract][Full Text] [Related]
15. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
Yada K; Nogami K; Shima M
Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
[TBL] [Abstract][Full Text] [Related]
16. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
Saenko EL; Shima M; Rajalakshmi KJ; Scandella D
J Biol Chem; 1994 Apr; 269(15):11601-5. PubMed ID: 7512568
[TBL] [Abstract][Full Text] [Related]
17. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.
Meeks SL; Cox CL; Healey JF; Parker ET; Doshi BS; Gangadharan B; Barrow RT; Lollar P
Blood; 2012 Sep; 120(12):2512-20. PubMed ID: 22855607
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.
Peters RT; Toby G; Lu Q; Liu T; Kulman JD; Low SC; Bitonti AJ; Pierce GF
J Thromb Haemost; 2013 Jan; 11(1):132-41. PubMed ID: 23205847
[TBL] [Abstract][Full Text] [Related]
19. Purification and characterization of factor VIII 372-Cys: a hypofunctional cofactor from a patient with moderately severe hemophilia A.
O'Brien DP; Pattinson JK; Tuddenham EG
Blood; 1990 Apr; 75(8):1664-72. PubMed ID: 2109644
[TBL] [Abstract][Full Text] [Related]
20. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
